Femasys (NASDAQ:FEMY) Posts Quarterly Earnings Results

Femasys (NASDAQ:FEMY) released its quarterly earnings data on Friday. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.07, Zacks reports. Femasys had a negative net margin of 534.36% and a negative return on equity of 225.97%.

Femasys Price Performance

FEMY traded up $0.02 during trading hours on Friday, hitting $1.42. The company’s stock had a trading volume of 52,887 shares, compared to its average volume of 251,829. The business’s 50-day moving average price is $1.99 and its 200-day moving average price is $5.67. Femasys has a 12 month low of $1.25 and a 12 month high of $20.80. The stock has a market cap of $11.90 million, a price-to-earnings ratio of -0.40 and a beta of -2.13. The company has a current ratio of 2.14, a quick ratio of 0.55 and a debt-to-equity ratio of 0.89.

Wall Street Analysts Forecast Growth

FEMY has been the topic of several research reports. Lake Street Capital reduced their target price on Femasys to $10.00 and set a “buy” rating on the stock in a report on Tuesday, August 18th. Wall Street Zen downgraded Femasys from a “sell” rating to a “strong sell” rating in a research report on Sunday, November 8th. Weiss Ratings lowered Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. Finally, Maxim Group cut their price target on Femasys to $10.00 and set a “buy” rating for the company in a report on Friday, August 14th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Femasys currently has an average rating of “Moderate Buy” and an average price target of $50.00.

Femasys Company Profile

Femasys Inc. is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures. Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.